-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Psoriatic arthritis (PsA) is a chronic, progressive, and inflammatory arthritis with an estimated global prevalence of 0.
2%-0.
3%, causing a considerable economic burden on the family and society
.
Recently, a randomized trial published in Ann Rheum Dis evaluated the efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tiralizumab in patients with psoriatic arthritis (PsA)
In this randomized, double-blind, placebo-controlled phase IIb study, the researchers included patients with active PsA who were randomized to receive tilapizumab 200 mg at a ratio of 1:1:1:1, once every 4 weeks (Q4W); Tilatuzumab 200, 100 or 20 mg Q12W; or placebo Q4W
.
Patients who received tiralizumab 20 mg or placebo switched to tiralizumab 200 mg Q12W at W24; treatment continued until W52
As a result, 391/500 screened patients received randomization and treatment
.
In W24, 71.
In summary, the results of this study show that tiralizumab treatment can significantly improve the joint and skin manifestations of PsA, but does not include wrist arthritis and tendinitis
.
As of W52, the treatment is generally well tolerated
Original source:
Philip J Mease, et al.
Leave a message here
